Combining Thymosin Alpha-1 with Dexamethasone Improves Sepsis Survival in Mice by Restoring Immune Cell Balance

Among five treatment groups, mice receiving the combination of dexamethasone (DXM) and thymosin alpha-1 (Tα1) timed to dendritic cell number changes had the highest survival rate. Tα1 increased dendritic cell numbers in vivo while DXM reduced them — when combined in a timed approach, they normalized DC numbers during endotoxemia. The combination therapy decreased bacterial translocation to extra-intestinal organs and enhanced clearance of secondary infections. Neither drug alone significantly changed DC capacity to activate T cells or expression of MHCII/CD86.

Endotoxemic BALB/c mice were randomly divided into five treatment groups receiving different combinations and timing of dexamethasone and thymosin alpha-1. Researchers measured dendritic cell numbers, MHCII and CD86 expression, T cell activation capacity, survival rates, TNF-α and IL-10 cytokine levels, bacterial translocation to organs, and secondary infection clearance. Both in vitro and in vivo assessments were performed.

Sepsis remains one of the leading causes of death in intensive care units, and immune dysfunction — not just the initial infection — drives mortality. This study demonstrates that intelligently combining an immune-boosting peptide with an anti-inflammatory steroid, timed to the patient's immune state, could be more effective than either alone. The concept of timing immunotherapy to immune cell dynamics is a sophisticated approach that could inform clinical sepsis management.

Thymosin alpha-1 is already approved in some countries for immune modulation in hepatitis and cancer. Combining it with dexamethasone — a widely available and inexpensive steroid — for sepsis represents a pragmatic combination that could be implemented relatively quickly. The study's approach of timing therapy to immune cell dynamics aligns with the broader trend toward personalized, biomarker-guided immunotherapy in critical care, moving beyond one-size-fits-all treatment protocols.

This is a mouse endotoxemia model, which simplifies the complex pathophysiology of human sepsis. The number of animals per group and specific survival rates were not detailed in the abstract. Endotoxemia models use a single bacterial toxin rather than actual polymicrobial infection. The timing of therapy based on DC numbers, while conceptually elegant, would be difficult to implement clinically without rapid DC monitoring tools. Long-term outcomes beyond survival were not assessed.